Chikwata chekutsvagisa kuCancer Research Institute (CSI) yeNational University yeSingapore yakagadzira mushonga wepeptide unonzi FFW unogona kudzivirira kukura kwehepatocellular carcinoma (HCC) kana yekutanga. gomarara rechiropa . Uku kuwanikwa kwakakosha kunovhura musuwo wekurapa kunoshanda kwegomarara rechiropa uye kuderedzwa mhedzisiro.
SALL4 is a protein associated with tumor growth and has been used as a prognostic marker and drug target for HCC, lung cancer and leukemia. It is usually present in a growing fetus, but is inactive in adult tissues. In some cancers, such as HCC, SALL4 is reactivated, leading to tumarara kukura.
Mamorekuru emishonga anoshanda pamapuroteni, akadai seSALL4-NuRD, kazhinji anoda puroteni yakanangwa kuti ive ne "muhomwe" diki mune yayo 3-D chimiro, uko mamorekuru emishonga anogona kuvapo nekushanda. Mukutsvaga kwekutanga, zvakaonekwa kuti SALL4 protein inosangana neimwe protein NuRD, ichiumba mubatanidzwa wakakosha mukusimudzirwa kwekenza senge HCC. SALL4 yakagadzirirwa neiyi timu yekutsvagisa haina kutsvaga 'homwe', asi yakagadzirirwa biomolecule iyo inovhara kudyidzana pakati peSALL4 neNuRD. Zvidzidzo zvakaona kuti kuvharira kubatana uku kunogona kukonzera bundu sero kufa uye kudzikamisa bundu maseru kufamba.
FFW can effectively block protein-protein interactions, and does not require “pockets” to take effect. The research team also found that when combined with sorafenib, FFW can reduce the growth of sorafenib-resistant HCC. Although most zvakanangwa kurapwa are small-molecule drugs, well-designed peptide drugs (such as FFW) tend to have higher selectivity than large-molecule surfaces and are less toxic than small molecules.
Muongorori weSingapore Dr. Liu Bee Hui akati: Zvichibva neruzivo rwatakatora kubva muchimiro uye nepasirese geni kutaura, isu tinoramba tichidzidza iyi peptide uye mamwe ma peptide ane zvivakwa zvakafanana kuti tigopedzisira tavaita mishonga yemakiriniki uye kuunza varwere kubatsirwa.
